Influence of SiRNA targeting survivin on chemosensitivity of H460/cDDP lung cancer cells

Journal of International Medical Research

Volumn 36, Issue 4, 2008, Pages 734-747

  Yang, H ^a   Fu, J H ^a   Hu, Y ^a   Huang, W Z ^a   Zheng, B ^a   Wang, G ^a   Zhang, X ^a   Wen, J ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Apoptosis; Chemosensitivity; Drug resistance; Drug therapy; Lung cancer; RNA interference; siRNA; Survivin

Indexed keywords

CASPASE 3; CISPLATIN; LIPOCORTIN 5; LIPOSOME; MESSENGER RNA; PACLITAXEL; SMALL INTERFERING RNA; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CDDP CELL; CELL LINE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME DEGRADATION; GENETIC TRANSFECTION; H460 CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG CANCER; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN TARGETING; WESTERN BLOTTING; CHEMISTRY; DRUG RESISTANCE; GENETICS; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PACLITAXEL; RNA, SMALL INTERFERING;

EID: 52049083683     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600416     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Ravdin PM, Davis G: Prognosis of patients with resected non-small cell lung cancer: impact of clinicnl and pathologic variables. Lung Cancer 2006; 52: 207-212.
3. Roninson IB: Tumor senescence as a determinant of drug response in vivo. Drug Resist Updat 2002; 5: 204-208.
4. Ng CP, Bonavida B: A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv Cancer Res 2002; 85: 145-174.
5. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
6. Tamm I, Wang Y, Sausville E, et al: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320.
7. Song Z, Yao X, Wu M: Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 2003; 278: 23130-23140.
8. Li F, Ambrosini G, Chu EY, et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584.
9. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
10. Falleni M, Pellegrini C, Marchetti A, et al: Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 2003; 200: 620-626.
11. Nakano J, Huang CL, Liu D, et al: Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. Int J Oncol 2005; 27: 1215-1221.
12. Monzo M, Rosell R, Felip E, et al: A novel antiapoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17: 2100-2104.
13. Karczmarek-Borowska B, Filip A, Wojcierowski J, et al: Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study. Folia Histochem Cytobiol 2005; 43: 237-242.
14. Ikehara M, Oshita F, Kameda Y, et al: Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol Rep 2002; 9: 835-838.
15. Yonesaka K, Tamura K, Kurata T, et al: Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 2006; 118: 812-820.
16. Zhang MC, Hu CP, Chen Q, et al: Experimental study of antisense oligodeoxynucleotide targeting survivin gene for cisplatin resistant human lung adeno-carcinoma xenograft in nude mice. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006; 31: 717-722 [in Chinese].
17. Zhang MC, Hu CP, Chen Q: Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells. Zhonghua Zhong Liu Za Zhi 2006; 28: 408-412 [in Chinese].
18. Wang T, Xu J, Zhong NS: Establishment of a human large cell lung cancer multi-drug resistance cell line H460/cDDP and its biological characteristics. China Oncol 2004; 14: 222-225 [in Chinese].
19. Chawla-Sarkar M, Bae SI, Reu FJ, et al: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004; 11: 915-923.
20. Giodini A, Kallio MJ, Wall NR, et al: Regulation of microtubule stability and mitotic progression by survivin. Cancer Res 2002; 62: 2462-2467.
21. Zaffaroni N, Pennati M, Colella G, et al: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59: 1406-1412.
22. c2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000; 97: 13103-13107.
23. Ohmori T, Morikage T, Sugimoto Y, et al: The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/ CDDP). Jpn J Cancer Res 1993; 84: 83-92.
24. Parker RJ, Eastman A, Bostick-Bruton F, et al: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87: 772-777.
25. Meijer C, Mulder NH, Timmer-Bosscha H, et al: Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 1992; 52: 6885-6889.
26. Kelley SL, Basu A, Teicher BA, et al: Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813-1815.
27. Yokomizo A, Ono M, Nanri H, et al: Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 1995; 55: 4293-4296.
28. Reardon JT, Vaisman A, Chaney SG, et al: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-aceto-ammine-dichlorocyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999; 59: 3968-3971.
29. Fink D, Aebi S, Howell SB: The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4: 1-6.
30. Wang T, Xu J, Zhong NS: Relationship between the acquired multi-drug resistance of human large cell lung cancer cell line NCI-H460 by cisplatin selection and p53 mutation. Zhonghua Jie He He Hu Xi Za Zhi 2005; 28: 102-107 [in Chinese].
31. Hoffman WH, Biade S, Zilfou JT, et al: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-3257.
32. Zhu N, Gu L, Findley HW, et al: An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncegene 2004; 23: 7545-7551.
33. Vegran F, Boidot R, Oudin C, et al: Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 2007; 26: 290-297.
34. Xia F, Altieri DC: Mitosis-independent survivin gene expression in vivo and regulation by p53. Cancer Res 2006; 66: 3392-3395.